PDS Biotechnology Corp (PDSB) stock
PDSBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.89−0.03 (-3.28%)
Close on Nov 17, 2026Market cap $50.03MP/E –Yield –
PDS Biotechnology total assets
Total assets on the balance sheet at the end of each period.
PDS Biotechnology's total assets was $8.81M at Jun 30, 2026. For fiscal 2025 it was $30.49M, down 32.8% from the year before. Over ten years it grew -13.8% a year on average. The highest annual figure on record is $134.09M in fiscal 2015.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.49M | -32.8% |
| FY2024 | Dec 31, 2024 | $45.36M | -23.6% |
| FY2023 | Dec 31, 2023 | $59.39M | -22.9% |
| FY2022 | Dec 31, 2022 | $77.01M | +14.6% |
| FY2021 | Dec 31, 2021 | $67.20M | +117.5% |
| FY2020 | Dec 31, 2020 | $30.89M | +113.2% |
| FY2019 | Dec 31, 2019 | $14.49M | +8713.0% |
| FY2018 | Dec 31, 2018 | $164.43K | -99.8% |
| FY2017 | Dec 31, 2017 | $92.62M | -16.5% |
| FY2016 | Dec 31, 2016 | $110.91M | -17.3% |
| FY2015 | Dec 31, 2015 | $134.09M | +696.0% |
| FY2014 | Dec 31, 2014 | $16.85M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $8.81M | -78.2% |
| Q1 FY2026 | Mar 31, 2026 | $24.66M | -47.6% |
| Q4 FY2025 | Dec 31, 2025 | $30.49M | -32.8% |
| Q3 FY2025 | Sep 30, 2025 | $34.71M | -33.8% |
| Q2 FY2025 | Jun 30, 2025 | $40.48M | -33.1% |
| Q1 FY2025 | Mar 31, 2025 | $47.03M | -31.8% |
| Q4 FY2024 | Dec 31, 2024 | $45.36M | -23.6% |
| Q3 FY2024 | Sep 30, 2024 | $52.45M | -8.3% |
| Q2 FY2024 | Jun 30, 2024 | $60.50M | -5.1% |
| Q1 FY2024 | Mar 31, 2024 | $69.01M | +0.8% |
| Q4 FY2023 | Dec 31, 2023 | $59.39M | -22.9% |
| Q3 FY2023 | Sep 30, 2023 | $57.19M | -23.6% |
| Q2 FY2023 | Jun 30, 2023 | $63.75M | +13.8% |
| Q1 FY2023 | Mar 31, 2023 | $68.45M | +12.1% |
| Q4 FY2022 | Dec 31, 2022 | $77.01M | +14.6% |
| Q3 FY2022 | Sep 30, 2022 | $74.89M | +4.4% |
| Q2 FY2022 | Jun 30, 2022 | $56.00M | -27.6% |
| Q1 FY2022 | Mar 31, 2022 | $61.04M | +119.9% |
| Q4 FY2021 | Dec 31, 2021 | $67.20M | +117.5% |
| Q3 FY2021 | Sep 30, 2021 | $71.75M | +108.3% |
| Q2 FY2021 | Jun 30, 2021 | $77.39M | +285.2% |
| Q1 FY2021 | Mar 31, 2021 | $27.76M | +16.0% |
| Q4 FY2020 | Dec 31, 2020 | $30.89M | +113.2% |
| Q3 FY2020 | Sep 30, 2020 | $34.45M | +77.7% |
| Q2 FY2020 | Jun 30, 2020 | $20.09M | -22.1% |
| Q1 FY2020 | Mar 31, 2020 | $23.93M | -22.9% |
| Q4 FY2019 | Dec 31, 2019 | $14.49M | +8713.0% |
| Q3 FY2019 | Sep 30, 2019 | $19.38M | -48.5% |
| Q2 FY2019 | Jun 30, 2019 | $25.80M | -45.3% |
| Q1 FY2019 | Mar 31, 2019 | $31.05M | -59.5% |
| Q4 FY2018 | Dec 31, 2018 | $164.43K | -99.8% |
| Q3 FY2018 | Sep 30, 2018 | $37.67M | -62.8% |
| Q2 FY2018 | Jun 30, 2018 | $47.21M | -58.2% |
| Q1 FY2018 | Mar 31, 2018 | $76.61M | -23.3% |
| Q4 FY2017 | Dec 31, 2017 | $92.62M | -16.5% |
| Q3 FY2017 | Sep 30, 2017 | $101.24M | -13.2% |
| Q2 FY2017 | Jun 30, 2017 | $112.99M | – |
| Q1 FY2017 | Mar 31, 2017 | $99.90M | – |
| Q4 FY2016 | Dec 31, 2016 | $110.91M | – |
| Q3 FY2016 | Sep 30, 2016 | $116.58M | – |
See a number that looks wrong?